808770-39-0 Usage
Uses
Used in Pharmaceutical Research and Drug Development:
6-Chloro-4-Methoxy-pyridazin-3-ylaMine is utilized as a reactant in the synthesis of various organic compounds, particularly in the development of new drugs and pharmaceuticals. Its unique structure and functional groups make it a promising candidate for medicinal chemistry, where it can be further explored for its potential therapeutic applications.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 6-Chloro-4-Methoxy-pyridazin-3-ylaMine serves as a valuable building block for the production of new drugs. Its structural features and functional groups can be manipulated to create novel compounds with specific biological activities, making it a versatile component in the design and synthesis of pharmaceutical agents.
This chemical compound may be of particular interest to chemists, pharmacologists, and researchers in the pharmaceutical industry, who are constantly seeking new and innovative ways to develop effective treatments and therapies.
Check Digit Verification of cas no
The CAS Registry Mumber 808770-39-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,0,8,7,7 and 0 respectively; the second part has 2 digits, 3 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 808770-39:
(8*8)+(7*0)+(6*8)+(5*7)+(4*7)+(3*0)+(2*3)+(1*9)=190
190 % 10 = 0
So 808770-39-0 is a valid CAS Registry Number.
808770-39-0Relevant academic research and scientific papers
IMIDAZOPYRIDAZINONE COMPOUNDS AND USES THEREOF
-
Paragraph 0699; 0700, (2020/07/05)
The present invention relates to imidazopyridazinone compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating autoimmune, inflammatory, and neurodegenerative diseases by administering
TRIAZOLO COMPOUNDS
-
Page/Page column 40, (2014/05/24)
The present invention relates to compounds of formula (I) and its use for the treatment of neurological disorders.
FUSED HETEROCYCLES AS LCK INHIBITORS
-
Page/Page column 41-42, (2010/11/25)
There is provided fused heterocycles of imidazopyridazine or pyrazolopyrimidine derivative represented by the formula (I), which have excellent Lck inhibitory activity and are useful for a medicament particularly an immunosuppressive agent. [wherein one of Y and Z is C atom, and the other is N atom; -X-10 is -N (R1) - or the like, -R1 is hydrogen or the like, -A- is bond or the like, is cycloalkyl, aryl or the like, -E- is bond or the like, -R3 is aryl, aromatic heterocycle or the like, -R4, -R5 and -R6 are the same or different, each being hydrogen or the like.]
SULPHONAMIDE COMPOUNDS THAT MODULATE CHEMOKINE RECEPTOR ACTIVITY (CCR4)
-
Page/Page column 15, (2010/02/09)
The invention provides pyrimidine, pyridazine and triazine compounds for use in therapy.
